Replies to post #103248 on Biotech Values

[DewDiligence]

Now that there is a "road map" to approval (albeit a hard one), it's not inconceivable that another generic company could make a stab at it down the road.

I disagree. Given the substantial time and money it takes to develop a Lovenox generic (even with help from the FDA’s “roadmap”), the economic upside from potentially being the fourth or fifth entrant in the market would not be worth the investment, IMO.